ID   HIPK2_HUMAN             Reviewed;        1198 AA.
AC   Q9H2X6; Q75MR7; Q8WWI4; Q9H2Y1;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   06-JUN-2002, sequence version 2.
DT   05-OCT-2010, entry version 106.
DE   RecName: Full=Homeodomain-interacting protein kinase 2;
DE            Short=hHIPk2;
DE            EC=2.7.11.1;
GN   Name=HIPK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF LYS-228.
RC   TISSUE=Liver, and Testis;
RX   MEDLINE=21167386; PubMed=11267674; DOI=10.1016/S0167-4781(00)00308-0;
RA   Wang Y., Hofmann T.G., Runkel L., Haaf T., Schaller H., Debatin K.-M.,
RA   Hug H.;
RT   "Isolation and characterization of cDNAs for the protein kinase
RT   HIPK2.";
RL   Biochim. Biophys. Acta 1518:168-172(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Frontal cortex;
RA   Stukart G.C., Dias-Neto E.;
RT   "Sequencing of hHIPk2, a human homolog of mouse homeodomain
RT   interacting protein kinase 2.";
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=22737999; PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 8-1198 (ISOFORM 2).
RA   Pierantoni G.M., Benvenuto G., Chiariotti L., Fusco A.;
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH TRADD.
RX   MEDLINE=20490030; PubMed=11032752; DOI=10.1006/bbrc.2000.3700;
RA   Li X., Wang Y., Debatin K.-M., Hug H.;
RT   "The serine/threonine kinase HIPK2 interacts with TRADD, but not with
RT   CD95 or TNF-R1 in 293T cells.";
RL   Biochem. Biophys. Res. Commun. 277:513-517(2000).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=11798164; DOI=10.1006/bbrc.2001.6310;
RA   Pierantoni G.M., Bulfone A., Pentimalli F., Fedele M., Iuliano R.,
RA   Santoro M., Chiariotti L., Ballabio A., Fusco A.;
RT   "The homeodomain-interacting protein kinase 2 gene is expressed late
RT   in embryogenesis and preferentially in retina, muscle, and neural
RT   tissues.";
RL   Biochem. Biophys. Res. Commun. 290:942-947(2002).
RN   [7]
RP   INTERACTION WITH RANBP9, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   LYS-228.
RX   MEDLINE=22209020; PubMed=12220523; DOI=10.1016/S0006-291X(02)02020-X;
RA   Wang Y., Marion Schneider E., Li X., Duttenhoefer I., Debatin K.-M.,
RA   Hug H.;
RT   "HIPK2 associates with RanBPM.";
RL   Biochem. Biophys. Res. Commun. 297:148-153(2002).
RN   [8]
RP   INTERACTION WITH TP73; TP53 AND TP63, MUTAGENESIS OF LYS-228, AND
RP   FUNCTION.
RX   MEDLINE=22191252; PubMed=11925430; DOI=10.1074/jbc.M200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [9]
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, INTERACTION WITH TP53 AND
RP   CREBBP, MUTAGENESIS OF LYS-228, FUNCTION, AND INDUCTION.
RX   MEDLINE=21638685; PubMed=11740489; DOI=10.1038/ncb715;
RA   Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
RA   Will H., Schmitz M.L.;
RT   "Regulation of p53 activity by its interaction with homeodomain-
RT   interacting protein kinase-2.";
RL   Nat. Cell Biol. 4:1-10(2002).
RN   [10]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-228.
RX   PubMed=12907596;
RA   Moeller A., Sirma H., Hofmann T.G., Rueffer S., Klimczak E.,
RA   Droege W., Will H., Schmitz M.L.;
RT   "PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-
RT   mediated p53 phosphorylation and cell cycle arrest but is dispensable
RT   for the formation of HIPK domains.";
RL   Cancer Res. 63:4310-4314(2003).
RN   [11]
RP   FUNCTION, INTERACTION WITH DAXX, AND MUTAGENESIS OF LYS-228.
RX   PubMed=14678985;
RA   Hofmann T.G., Stollberg N., Schmitz M.L., Will H.;
RT   "HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-
RT   terminal kinase activation and apoptosis in human hepatoma cells.";
RL   Cancer Res. 63:8271-8277(2003).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH P53DINP1.
RX   MEDLINE=22863074; PubMed=12851404; DOI=10.1074/jbc.M301979200;
RA   Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B.,
RA   Soddu S., Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
RT   "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
RT   partners in regulating p53 activity.";
RL   J. Biol. Chem. 278:37722-37729(2003).
RN   [13]
RP   FUNCTION, INTERACTION WITH SKI; SMAD1; SMAD2 AND SMAD3, AND
RP   MUTAGENESIS OF LYS-228 AND 359-SER--TYR-361.
RX   MEDLINE=22877089; PubMed=12874272; DOI=10.1074/jbc.M307112200;
RA   Harada J., Kokura K., Kanei-Ishii C., Nomura T., Khan M.M., Kim Y.,
RA   Ishii S.;
RT   "Requirement of the co-repressor homeodomain-interacting protein
RT   kinase 2 for ski-mediated inhibition of bone morphogenetic protein-
RT   induced transcriptional activation.";
RL   J. Biol. Chem. 278:38998-39005(2003).
RN   [14]
RP   DESUMOYLATION.
RX   PubMed=16253240; DOI=10.1016/j.febslet.2005.10.010;
RA   Kim Y.H., Sung K.S., Lee S.-J., Kim Y.-O., Choi C.Y., Kim Y.;
RT   "Desumoylation of homeodomain-interacting protein kinase 2 (HIPK2)
RT   through the cytoplasmic-nuclear shuttling of the SUMO-specific
RT   protease SENP1.";
RL   FEBS Lett. 579:6272-6278(2005).
RN   [15]
RP   INTERACTION WITH CBX4, SUMOYLATION AT LYS-32, AND FUNCTION.
RX   PubMed=17018294; DOI=10.1016/j.molcel.2006.08.004;
RA   Roscic A., Moeller A., Calzado M.A., Renner F., Wimmer V.C.,
RA   Gresko E., Luedi K.S., Schmitz M.L.;
RT   "Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by
RT   its substrate protein HIPK2.";
RL   Mol. Cell 24:77-89(2006).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-361, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [17]
RP   FUNCTION, AND UBIQUITINATION BY FBXO3.
RX   PubMed=18809579; DOI=10.1128/MCB.00897-08;
RA   Shima Y., Shima T., Chiba T., Irimura T., Pandolfi P.P.,
RA   Kitabayashi I.;
RT   "PML activates transcription by protecting HIPK2 and p300 from
RT   SCFFbx3-mediated degradation.";
RL   Mol. Cell. Biol. 28:7126-7138(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-361, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=19534553; DOI=10.1021/pr900044c;
RA   Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,
RA   Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,
RA   Wiley H.S., Qian W.-J.;
RT   "An extensive survey of tyrosine phosphorylation revealing new sites
RT   in human mammary epithelial cells.";
RL   J. Proteome Res. 8:3852-3861(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-361; SER-827 AND
RP   THR-838, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-792 AND GLN-1027.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein kinase acting as a corepressor of several
CC       transcription factors, including SMAD1 and POU4F1/Brn3a and
CC       probably NK homeodomain transcription factors. Inhibits cell
CC       growth and promotes apoptosis. Involved in transcriptional
CC       activation of TP53 and TP73. Phosphorylation of TP53 may be
CC       mediated by a TP53-HIPK2-AXIN1 complex. In response to TGFB,
CC       cooperates with DAXX to activate JNK. Phosphorylates the
CC       antiapoptotic factor CTBP1 and promotes its proteasomal
CC       degradation. In the Wnt/beta-catenin signaling pathway acts as an
CC       intermediate kinase between TAK1 and NLK to promote the
CC       proteasomal degradation of MYB (By similarity). Phosphorylates
CC       CBX4 upon DNA damage and promotes its E3 SUMO-protein ligase
CC       activity. PML, HIPK2 and FBXO3 may act synergically to activate
CC       p53/TP53-dependent transactivation.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts with TRADD, TP53, TP73, TP63, CREBBP, DAXX,
CC       P53DINP1, SKI, SMAD1, SMAD2 and SMAD3, but not SMAD4. Interacts
CC       with NKX1-2, NKX2-5, SPN/CD43, UBE2I, HMGA1, CTBP1, AXIN1, NLK,
CC       MYB, POU4F1, POU4F2, POU4F3, UBE2I, UBL1. Probably part of a
CC       complex consisting of TP53, HIPK2 and AXIN1 (By similarity).
CC       Interacts with CBX4.
CC   -!- INTERACTION:
CC       Q13838:BAT1; NbExp=1; IntAct=EBI-348345, EBI-348622;
CC       P17096:HMGA1; NbExp=2; IntAct=EBI-348345, EBI-746843;
CC       P10242:MYB; NbExp=1; IntAct=EBI-348345, EBI-298355;
CC       Q9Y6I7:WSB1; NbExp=1; IntAct=EBI-348345, EBI-1171494;
CC   -!- SUBCELLULAR LOCATION: Nucleus, PML body. Cytoplasm.
CC       Note=Concentrated in PML/POD/ND10 nuclear bodies. Small amounts
CC       are cytoplasmic.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Experimental confirmation may be lacking for some
CC         isoforms;
CC       Name=1;
CC         IsoId=Q9H2X6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H2X6-2; Sequence=VSP_004805, VSP_004806, VSP_004807;
CC       Name=3;
CC         IsoId=Q9H2X6-3; Sequence=VSP_004804;
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, muscle and kidney.
CC       Weakly expressed in a ubiquitous way. Down-regulated in several
CC       thyroid and breast tumors.
CC   -!- INDUCTION: By UV irradiation.
CC   -!- PTM: Phosphorylated on tyrosines (By similarity).
CC       Autophosphorylated.
CC   -!- PTM: Sumoylated. When conjugated it is directed to nuclear
CC       speckles. Desumoylated by SENP1 (By similarity). Sumoylation on
CC       Lys-32 is promoted by the E3 SUMO-protein ligase CBX4.
CC   -!- PTM: Ubiquitinated by FBXO3, leading to rapid proteasome-dependent
CC       degradation. This degradation, but not ubiquitination, is
CC       prevented in the presence of PML.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. HIPK subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF208291; AAG41236.1; -; mRNA.
DR   EMBL; AF326592; AAL37371.1; -; mRNA.
DR   EMBL; AC005531; AAS00368.1; -; Genomic_DNA.
DR   EMBL; AC073184; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006021; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC141932; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF207702; AAG35710.1; -; mRNA.
DR   IPI; IPI00215949; -.
DR   IPI; IPI00215950; -.
DR   IPI; IPI00289892; -.
DR   RefSeq; NP_001106710.1; -.
DR   RefSeq; NP_073577.3; -.
DR   UniGene; Hs.724392; -.
DR   ProteinModelPortal; Q9H2X6; -.
DR   SMR; Q9H2X6; 195-530.
DR   IntAct; Q9H2X6; 7.
DR   MINT; MINT-234689; -.
DR   STRING; Q9H2X6; -.
DR   PhosphoSite; Q9H2X6; -.
DR   PRIDE; Q9H2X6; -.
DR   Ensembl; ENST00000406875; ENSP00000385571; ENSG00000064393.
DR   GeneID; 28996; -.
DR   KEGG; hsa:28996; -.
DR   UCSC; uc003vvd.2; human.
DR   UCSC; uc003vvf.2; human.
DR   CTD; 28996; -.
DR   GeneCards; GC07M139246; -.
DR   HGNC; HGNC:14402; HIPK2.
DR   HPA; HPA007611; -.
DR   MIM; 606868; gene.
DR   PharmGKB; PA29291; -.
DR   HOGENOM; HBG443763; -.
DR   HOVERGEN; HBG051908; -.
DR   InParanoid; Q9H2X6; -.
DR   OrthoDB; EOG9FXTT0; -.
DR   PhylomeDB; Q9H2X6; -.
DR   BRENDA; 2.7.11.1; 247.
DR   NextBio; 51926; -.
DR   PMAP-CutDB; Q9H2X6; -.
DR   ArrayExpress; Q9H2X6; -.
DR   Bgee; Q9H2X6; -.
DR   CleanEx; HS_HIPK2; -.
DR   Genevestigator; Q9H2X6; -.
DR   GermOnline; ENSG00000064393; Homo sapiens.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0046332; F:SMAD binding; IPI:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0046790; F:virion binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by...; IDA:BHF-UCL.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IMP:UniProtKB.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:0030511; P:positive regulation of transforming growth ...; IMP:UniProtKB.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0006350; P:transcription; IEA:UniProtKB-KW.
DR   GO; GO:0019048; P:virus-host interaction; NAS:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; ATP-binding; Complete proteome;
KW   Cytoplasm; Isopeptide bond; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Serine/threonine-protein kinase;
KW   Transcription; Transcription regulation; Transferase; Ubl conjugation.
FT   CHAIN         1   1198       Homeodomain-interacting protein kinase 2.
FT                                /FTId=PRO_0000085995.
FT   DOMAIN      199    527       Protein kinase.
FT   NP_BIND     205    213       ATP (Probable).
FT   REGION       97    230       Transcriptional corepression (By
FT                                similarity).
FT   REGION      189    520       Interaction with DAXX.
FT   REGION      539    844       Interaction with SKI and SMAD1.
FT   REGION      752    897       Interaction with POU4F1 (By similarity).
FT   REGION      774    876       Interaction with CTBP1 (By similarity).
FT   REGION      787    897       Interaction with HMGA1 (By similarity).
FT   REGION      846    941       Interaction with TP53 and TP73.
FT   REGION      873    980       Required for localization to nuclear
FT                                speckles (By similarity).
FT   REGION      873    907       Interaction with UBE2I (By similarity).
FT   REGION      935   1049       Interaction with AXIN1 (By similarity).
FT   COMPBIAS   1088   1094       Poly-Ala.
FT   ACT_SITE    324    324       Proton acceptor (Probable).
FT   BINDING     228    228       ATP (Probable).
FT   MOD_RES     361    361       Phosphotyrosine.
FT   MOD_RES     827    827       Phosphoserine.
FT   MOD_RES     838    838       Phosphothreonine.
FT   CROSSLNK     32     32       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   CROSSLNK   1191   1191       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO) (By
FT                                similarity).
FT   VAR_SEQ     595    621       Missing (in isoform 3).
FT                                /FTId=VSP_004804.
FT   VAR_SEQ     808    907       Missing (in isoform 2).
FT                                /FTId=VSP_004805.
FT   VAR_SEQ     989   1018       VNTSHHSSSYKSKSSSNVTSTSGHSSGSSS -> GNLGPGQ
FT                                GRNLSLESGFPAFLLLEMLLYGS (in isoform 2).
FT                                /FTId=VSP_004806.
FT   VAR_SEQ    1019   1198       Missing (in isoform 2).
FT                                /FTId=VSP_004807.
FT   VARIANT     792    792       R -> Q.
FT                                /FTId=VAR_040547.
FT   VARIANT    1027   1027       R -> Q.
FT                                /FTId=VAR_040548.
FT   MUTAGEN     228    228       K->A: Locates in the nucleoplasm, no
FT                                effect on interaction with RANBP9.
FT   MUTAGEN     228    228       K->R: Abolishes enzymatic activity, no
FT                                effect on interaction with TP53 and TP73
FT                                or on BMP-induced transcriptional
FT                                activation. Enhances BMP-induced
FT                                transcriptional activation; when
FT                                associated with 359-AAF-361.
FT   MUTAGEN     359    361       STY->AAF: Enhances BMP-induced
FT                                transcriptional activation; when
FT                                associated with R-228.
FT   CONFLICT     33     33       I -> V (in Ref. 1; AAG41236).
FT   CONFLICT     59     59       L -> P (in Ref. 1; AAG41236).
FT   CONFLICT     64     64       T -> S (in Ref. 1; AAG41236).
FT   CONFLICT    169    169       S -> F (in Ref. 4; AAG35710).
FT   CONFLICT    187    187       V -> S (in Ref. 4; AAG35710).
FT   CONFLICT    202    202       L -> S (in Ref. 4; AAG35710).
FT   CONFLICT    233    233       H -> R (in Ref. 1; AAG41236).
FT   CONFLICT    471    471       N -> I (in Ref. 2; AAL37371).
FT   CONFLICT    669    669       P -> S (in Ref. 4; AAG35710).
FT   CONFLICT    711    711       T -> N (in Ref. 4; AAG35710).
FT   CONFLICT    717    719       PPA -> SPT (in Ref. 4; AAG35710).
FT   CONFLICT    724    724       T -> D (in Ref. 4; AAG35710).
SQ   SEQUENCE   1198 AA;  130966 MW;  6022D5710E8D2D93 CRC64;
     MAPVYEGMAS HVQVFSPHTL QSSAFCSVKK LKIEPSSNWD MTGYGSHSKV YSQSKNIPLS
     QPATTTVSTS LPVPNPSLPY EQTIVFPGST GHIVVTSASS TSVTGQVLGG PHNLMRRSTV
     SLLDTYQKCG LKRKSEEIEN TSSVQIIEEH PPMIQNNASG ATVATATTST ATSKNSGSNS
     EGDYQLVQHE VLCSMTNTYE VLEFLGRGTF GQVVKCWKRG TNEIVAIKIL KNHPSYARQG
     QIEVSILARL STESADDYNF VRAYECFQHK NHTCLVFEML EQNLYDFLKQ NKFSPLPLKY
     IRPVLQQVAT ALMKLKSLGL IHADLKPENI MLVDPSRQPY RVKVIDFGSA SHVSKAVCST
     YLQSRYYRAP EIILGLPFCE AIDMWSLGCV IAELFLGWPL YPGASEYDQI RYISQTQGLP
     AEYLLSAGTK TTRFFNRDTD SPYPLWRLKT PDDHEAETGI KSKEARKYIF NCLDDMAQVN
     MTTDLEGSDM LVEKADRREF IDLLKKMLTI DADKRITPIE TLNHPFVTMT HLLDFPHSTH
     VKSCFQNMEI CKRRVNMYDT VNQSKTPFIT HVAPSTSTNL TMTFNNQLTT VHNQAPSSTS
     ATISLANPEV SILNYPSTLY QPSAASMAAV AQRSMPLQTG TAQICARPDP FQQALIVCPP
     GFQGLQASPS KHAGYSVRME NAVPIVTQAP GAQPLQIQPG LLAQQAWPSG TQQILLPPAW
     QQLTGVATHT SVQHATVIPE TMAGTQQLAD WRNTHAHGSH YNPIMQQPAL LTGHVTLPAA
     QPLNVGVAHV MRQQPTSTTS SRKSKQHQSS VRNVSTCEVS SSQAISSPQR SKRVKENTPP
     RCAMVHSSPA CSTSVTCGWG DVASSTTRER QRQTIVIPDT PSPTVSVITI SSDTDEEEEQ
     KHAPTSTVSK QRKNVISCVT VHDSPYSDSS SNTSPYSVQQ RAGHNNANAF DTKGSLENHC
     TGNPRTIIVP PLKTQASEVL VECDSLVPVN TSHHSSSYKS KSSSNVTSTS GHSSGSSSGA
     ITYRQQRPGP HFQQQQPLNL SQAQQHITTD RTGSHRRQQA YITPTMAQAP YSFPHNSPSH
     GTVHPHLAAA AAAAHLPTQP HLYTYTAPAA LGSTGTVAHL VASQGSARHT VQHTAYPASI
     VHQVPVSMGP RVLPSPTIHP SQYPAQFAHQ TYISASPAST VYTGYPLSPA KVNQYPYI
//
